Table II.
Sanger-sequencing detected mutations and their properties.
| Patient code | Mutation | Amino acid changes | BCR/ABL % (IS) | BCR/ABL type | Exon | Treatmenta |
|---|---|---|---|---|---|---|
| 3 | D241G (heterozygous) | GACàGGC (A>G) | 42.9 | p210 | Exon 4 (p-loop) | Imatinib |
| 4 | E255K (homozygous) | GAGàAAG (G>A) | 0.151 | p210 | Exon 4 (p-loop) | Glivec |
| 5 | E255K (homozygous) | GAGàAAG (G>A) | 4.43 | p210 | Exon 4 (p-loop) | Nilotinib |
| 7 | E255K (homozygous) | GAGàAAG (G>A) | 0.81 | p210 | Exon 4 (p-loop) | Imatinib |
| 9 | D241G (heterozygous) | GACàGGC (A>G) | 8.35 | p210 | Exon 4 (p-loop) | Dasatinib |
| 10 | E255K (homozygous) | GAGàAAG (G>A) | 38.4 | p210 | Exon 4 (p-loop) | Nilotinib |
| 28 | K285N (homozygous) | AAAàAAT (A>T) | 0.362 | p210 | Exon 5 (IM B.S.) | Imavec |
| 14 | C369C (heterozygous) | TGCà TGT (C>T) | 0.0013 | p210 | Exon 7 (C-loop) | Dasatinib |
| 24 | A380T (heterozygous) | GCTàACT (G>A) | 0.15 | p210 | Exon 7 (A-loop) | Dasatinib |
| 15 | C369C (heterozygous) | TGCà TGT (C>T) | 0.02 | p210 | Exon 7 (C-loop) | Dasatinib |
| 40 | A366V (heterozygous) | GCCàGTC (C>T) | 0.003 | p210 | Exon 7 (C-loop) | Nilotinib |
a
Used TKI after mutation detection. IS, international scale at mutation detection; BCR, breakpoint cluster region; ABL, Abelson.